NEW YORK — Fios Genomics will provide bioinformatics, statistics, and computational biology services to Charles River Laboratories International under a partnership announced Thursday.
Edinburgh, UK-based Fios Genomics will help Charles River, of Wilmington, Massachusetts, with sourcing and analysis of multi-variant datasets to inform drug discovery. These datasets will cover microarrays, next-generation sequencing, proteomics, metabolomics, and epigenetics, plus the associated metadata, the companies said.
"The explosion in omics data has been a boon for the drug discovery industry, but analysis and interpretation of these datasets are challenging. Through our partnership with Fios Genomics, Charles River clients will have greater access to the special combination of skills in bioinformatics, statistics, and biology required to obtain meaningful information from their data," said Birgit Girshick, Charles River's corporate executive vice president for discovery & safety assessment, biologics testing solutions, and avian vaccine services.
"Our approach to bioinformatics at Fios Genomics is to look beyond algorithms and statistics and understand that biological relevance and statistical significance are not necessarily the same thing," Fios Genomics CEO Sarah Lynagh said in a statement. "Bioinformatics is about biology, outcome, and pathways, and by partnering with Charles River, we can help more researchers make data-driven decisions about their programs that are grounded in biological insights."